Stocktoria

Celularity Inc CELU

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-05-23

Celularity Inc statistics & valuation

Market cap$17.9M
P / S0.7×
Net margin-345.4%
Return on capital-230.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-1458.40% -469.30% 79.00% -862.00% -106.80% -345.40% 2019202020212022202320242025
Gross margin (%)
65.50% 54.80% -9.40% 29.70% 2019202020212022202320242025
Operating margin (%)
-1064.00% -511.20% -142.40% -844.40% -70.70% -230.90% 2019202020212022202320242025
Return on equity (%)
-100.70% 7.10% -479.20% -655.10% 2019202020212022202320242025
Shares outstanding
18.5M 124.3M 15.0M 193.8M 22.5M 28.8M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
0.90% -48.30% -24.20% 3.50% -136.40% -43.60% -85.50% 2019202020212022202320242025
Free cash flow margin (%)
-637.50% -545.10% -796.20% -174.50% -12.10% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$1.49 $0.95 -$11.02 -$2.64 -$3.59 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin——29.7%-9.4%54.8%65.5%—
Operating margin-230.9%-70.7%-844.4%-142.4%-511.2%-1064.0%—
Net margin-345.4%-106.8%-862.0%79.0%-469.3%-1458.4%—
FCF margin—-12.1%-174.5%-796.2%-545.1%-637.5%—
Return on assets-85.5%-43.6%-136.4%3.5%-24.2%-48.3%0.9%
Return on equity241.0%-655.1%-479.2%7.1%-100.7%39.2%-0.8%
Current ratio0.150.380.290.542.252.704.40

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.